Your session is about to expire
← Back to Search
Evidence Impact on Biologics Confidence for Psoriasis
N/A
Waitlist Available
Led By Steve R Feldman, MD, PhD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosed with psoriasis (ICD-9: 696.1)
Age 18-80
Must not have
Currently or previously managed with a biologic medication
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Summary
This trial will study whether patients are more confident in the potential success of biologic medications in treating their psoriasis after being presented with clinical trial evidence, anecdotal evidence, or both.
Who is the study for?
This trial is for adults aged 18-80 with psoriasis who have never been treated with biologic medications. It aims to understand if different types of evidence can boost their confidence in using these drugs.
What is being tested?
The study tests whether presenting patients with clinical trial evidence, anecdotal evidence, both, or no evidence affects their confidence in the success of biologic medications for treating psoriasis.
What are the potential side effects?
Since this study focuses on patient perceptions rather than drug effects, it does not directly involve side effects. However, common side effects of biologics may include injection site reactions and increased risk of infections.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with psoriasis.
Select...
I am between 18 and 80 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been treated with biologic medication.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 day
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Oral survey responses
Trial Design
4Treatment groups
Active Control
Placebo Group
Group I: Anecdotal + Research Study EvidenceActive Control1 Intervention
Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence and anecdotal evidence.
Group II: Anecdotal EvidenceActive Control1 Intervention
Scenario describes a medication's (biologic's) therapeutic effect results based on anecdotal evidence.
Group III: Research Study EvidenceActive Control1 Intervention
Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence.
Group IV: No EvidencePlacebo Group1 Intervention
Scenario describes a medication's (biologic's) therapeutic effect with no mention on anecdotal nor research study evidence.
Find a Location
Who is running the clinical trial?
Wake Forest University Health SciencesLead Sponsor
1,394 Previous Clinical Trials
2,459,636 Total Patients Enrolled
12 Trials studying Psoriasis
601 Patients Enrolled for Psoriasis
Steve R Feldman, MD, PhDPrincipal InvestigatorWake Forest University Health Sciences
2 Previous Clinical Trials
210 Total Patients Enrolled
1 Trials studying Psoriasis
24 Patients Enrolled for Psoriasis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been treated with biologic medication.I am 18 years old or older.I am between 18 and 80 years old.I have been diagnosed with psoriasis.
Research Study Groups:
This trial has the following groups:- Group 1: Anecdotal + Research Study Evidence
- Group 2: Anecdotal Evidence
- Group 3: Research Study Evidence
- Group 4: No Evidence
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger